Counselor training and attitudes toward pharmacotherapies for opioid use disorder

Substance Abuse

Volumn 37, Issue 1, 2016, Pages 47-53

  Aletraris, Lydia ^a   Edmond, Mary Bond ^a   Paino, Maria ^b   Fields, Dail ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Buprenorphine; counselor attitudes; medicationassisted treatment; methadone; opioid agonist therapy; opioid use disorder; substance abuse

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANTAGONIST;

ATTITUDE TO HEALTH; COMPARATIVE STUDY; COUNSELOR; EDUCATION; FEMALE; HUMAN; INFORMATION DISSEMINATION; MALE; OPIOID-RELATED DISORDERS; PSYCHOLOGY;

BUPRENORPHINE; COUNSELORS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMATION DISSEMINATION; MALE; METHADONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 84961203713     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2015.1062457     Document Type: Article

References (49)

1. Substance Abuse and Mental Health Services Administration. Heroin and Other Opiate Admissions to Substance Abuse Treatment: The TEDS Report. Rockville, MD: US Department of Health and Human Services; 2009.
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2008 National Survey on Drug Use and Health: National Findings. Office Of Applied Studies, NSDUH series H-36, HHS publication no. SMA 09-4434. Rockville, MD: US Department of Health and Human Services; 2009.
3. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2001-2011. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-65, HHS Publication No. (SMA) 13-4772. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
4. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005; 79: 113-116.
5. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug Alcohol Depend. 2004; 73: 219-226.
6. Barnett PG, Rodgers JH, Bloch DA. A meta-Analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001; 96: 683-690.
7. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction. 1998; 93: 475-486.
8. Ling W, Huber A, Rawson RA. New trends in opiate pharmacotherapy. Drug Alcohol Rev. 2001; 20: 79-94.
9. Schwartz RP, Kelly SM, O'Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008; 17: 396-401.
10. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-Tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949-958.
11. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003; 70: S49-S57.
12. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009; 104: 73-77.
13. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse. 2002; 28: 231-241.
14. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005; 100: 1090-1100.
15. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. Am J Addict. 2004; 13: S42-S66.
16. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005; 20: 1038-1041.
17. Knudsen HK, Abraham AJ, Johnson JA, Roman PM. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009; 37: 307-312.
18. Knudsen HK, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med. 2010; 4: 99-107.
19. Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007; 32: 207-215.
20. Rogers EM. The Diffusion of Innovations. 4th ed. New York: Free Press; 2003.
21. Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011; 56 (Suppl 1): S68-S75.
22. Hubbard SM, Huang JY, Mulvey KP. Application of diffusion of innovations theory to the TIPs evaluation project results and beyond. Eval Program Plann. 2003; 26: 99-107.
23. Damschroder L, Aron D, Keith R, Kirsh S, Alexander J. Lowery J. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implement Sci. 2009; 4: 50-64.
24. Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005; 29: 95-106.
25. Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. J Subst Abuse Treat. 2011; 41: 374-385.
26. Knudsen HK, Ducharme LJ, Roman PM. Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. Am J Addict. 2007; 16: 365-371.
27. Andrews S, Sorensen JL, Guydish J, Delucchi K, Greenberg B. Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. J Maint Addict. 2005; 3: 47-59.
28. Klein KJ, Sorra JS. The challenge of innovation implementation. Acad Manage Rev. 1996; 21: 1055-1080.
29. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R. Research to practice: Adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003; 24: 1-11.
30. Fletcher AM. Inside Rehab. New York, NY: Viking; 2013.
31. Kelly JF. Self-help for substance-use disorders: history, effectiveness, knowledge gaps, and research opportunities. Clin Psychol Rev. 2003; 23: 639-663.
32. Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009; 70: 628-635.
33. Lehman WEK, Greener JM, Simpson DD. Assessing organizational readiness for change. J Subst Abuse Treat. 2002; 22: 197-209.
34. Simpson DD. A conceptual framework for transferring research to practice. J Subst Abuse Treat. 2002; 22: 171-182.
35. Cohen WM, Levinthal DA. Absorptive capacity: A new perspective on learning and innovation. Admin Sci Q. 1990; 35: 128-152.
36. Fuller BE, Rieckmann T, Nunes EV, et al. Organizational readiness for change and opinions toward treatment innovations. J Subst Abuse Treat. 2007; 33: 183-192.
37. Substance Abuse and Mental Health Services Administration. The NSDUH Report: State Estimates of Nonmedical Use of Prescription Pain Relievers. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2013.
38. Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. It takes your heart: The image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1985; 20: 1751-1771.
39. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002; 79: 571-578.
40. Mee-Lee DL, Gartner L, Miller MM, Shulman GD, Wilford BB. Patient Placement Criteria for the Treatment of Substance Related Disorders. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine; 1996.
41. Kasarabada N, Hser Y-I, Parker L, Hall E, Anglin M, Chang E. A self-Administered instrument for assessing therapeutic approaches of drug-user treatment counselors. Subst Use Misuse. 2001; 36: 273-299.
42. Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013; 44: 473-480.
43. Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat. 2001; 21: 1-9.
44. Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. Psych Addict Behav. 2011; 25: 194-205.
45. Davern M, McAlpine D, Beebe TJ, Ziegenfuss J, Rockwood T, Call KT. Are lower response rates hazardous to your health survey? An analysis of three state telephone health surveys. Health Serv. Res. 2010; 45 (5 Pt 1): 1324-1344.
46. Groves RM, Peytcheva E. The impact of nonresponse rates on nonresponse bias: A meta analysis. Public Opin Q. 2008; 72: 167-189.
47. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2012. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
48. Turner L, Kruszewski SP, Alexander FC. Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. Am J Addict. 2015; 24: 24-29.
49. National Association of Community Health Centers. Healthcare Reform Impact at a Glance: What's in It for Persons With Mental and Addiction Disorders. Washington, DC: National Council for Community Behavioral Healthcare; 2010.